Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
暂无分享,去创建一个
Richard Sylvester | Raoul Herbrecht | John E Bennett | Kieren A Marr | E. Thiel | R. Sylvester | R. Rubin | D. Denning | J. Wingard | R. Greene | J. Oestmann | O. Lortholary | K. Marr | J. Bennett | W. Kern | P. Stark | B. D. de Pauw | R. Herbrecht | M. Hodges | T. Patterson | P. Chandrasekar | P. Troke | David W Denning | P. Ribaud | D. Caillot | H. Schlamm | Olivier Lortholary | John R Wingard | Eckhard Thiel | Thomas F Patterson | Winfried V Kern | Denis Caillot | C. Durand | Robert H Rubin | Patricia Ribaud | Reginald E Greene | Haran T Schlamm | Jörg-W Oestmann | Paul Stark | Christine Durand | Peter F Troke | Pranatharthi H Chandrasekar | Michael R Hodges | Ben de Pauw
[1] Lawrence M. Friedman,et al. Data and Safety Monitoring Boards , 2002 .
[2] M. White. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] D. Bates,et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] L. Collette,et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] R. Herbrecht,et al. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability , 1999, Transplant infectious disease : an official journal of the Transplantation Society.
[6] E. Anaissie,et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.
[7] L S Freedman,et al. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. , 1976, Biometrics.
[8] E. Anaissie,et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] William R. Kirkpatrick,et al. Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes , 2000, Medicine.
[10] D. Denning,et al. Practice Guidelines for Diseases Caused by Aspergillus , 2000 .
[11] E. Thiel,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] E. Anaissie,et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] A. Espinel-Ingroff. In Vitro Fungicidal Activities of Voriconazole, Itraconazole, and Amphotericin B against Opportunistic Moniliaceous and Dematiaceous Fungi , 2001, Journal of Clinical Microbiology.
[14] E. Fishman,et al. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. , 1985, Radiology.